Frazier Life Sciences Acquisition Corp II (FLSC) Stock Price & Analysis
Frazier Life Sciences Acquisition Corp II (FLSC) closed at USD 10.49 on Thursday, October 15, 2026, up 1.94% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 10.29; the Oct 15, 2026 session ranged USD 10.23–10.5 on volume of 84,219 shares. Market capitalization is $101.49M, with a 52-week range of USD 10.18–10.5 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/FLSC.md
Key facts (FLSC)
- Analysts: None.
- Total return with dividends: 1Y +1.9% vs S&P 500 +18.1%; 5Y +0.0% vs S&P 500 +85.1%.
Analysts (FLSC)
Consensus None.
Total return (dividends reinvested) (FLSC)
| 1Y (from 2026-10-14) | 5Y (from 2026-10-12) | |
|---|---|---|
| Total return | +1.9% | +0.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 0.0% | 0.0% |
| Max drawdown | +0.0% (→) | +0.0% (→) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 10.49 |
|---|---|
| Change | ▲ 1.94% (up) |
| Previous Close | USD 10.29 |
| Open | USD 10.23 |
| Day Range | USD 10.23 – 10.5 |
| 52-Week Range | USD 10.18 – 10.5 |
| Volume | 84,219 shares |
| Market Cap | $101.49M |
| Exchange | NCM |
Analyst Ratings (FLSC)
Wall Street analysts rate FLSC "None", per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | None |
|---|
Earnings (FLSC)
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (FLSC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (FLSC)
Nexqual rates Frazier Life Sciences Acquisition Corp II's overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (FLSC)
| Shares Outstanding | 9.68M |
|---|
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (FLSC)
Frazier Life Sciences Acquisition Corp II is led by Albert Cha (age 53), CEO & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO & Director | Albert Cha (age 53) |
|---|---|
| Chief Financial Officer | Adams Francis Adams (age 44) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KCHV | Kochav Defense Acquisition Corp | USD 10.5 | ▲ 0% |
| TACH | Titan Acquisition Corp. | USD 10.54 | ▲ 0% |
| ALUB | Alussa Energy Acquisition Corp. | USD 10.14 | ▲ 0% |
| OIM | OneIM Acquisition Corp. | USD 10.12 | ▲ 0% |
| FVAV | Fortress Value Acquisition Corp | USD 10.14 | ▼ 0.1% |
| FCRS | FutureCrest Acquisition Corp. | USD 10.22 | ▲ 0.2% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt